Daratumumab (Darzalex) as first-line treatment in combination with lenalidomide and dexamethasone if a stem cell transplantation is not an option
In 2020 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of daratumumab in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma in people who can't have a stem cell transplantation.
The manufacturer gave IQWiG one ongoing study that provided at least some preliminary answers. A total of 737 patients participated in the study. 369 of them were given lenalidomide and dexamethasone, and 368 of them also received daratumumab.
These are the findings so far: